AMGN UNDERWEIGHT: Trim 20-25% at $444, Stop $436, Re-Entry $420-$432 or $394-$415
UNDERWEIGHT rating is chosen over SELL because the 0.41 defensive beta, 2.3% dividend, intact structural uptrend above $393, and catalyst stack (MariTide Phase 3, Repatha label expansion, Tezspire EoE filing) justify partial retention rather than full exit. The 20-25% trim is calibrated between the conservative analyst's 25-33% and neutral analyst's 15-20%, moderately below the 8/27 35-45% trigger conviction but above the 8/31 lighter-end principle due to deepened MACD negativity (-1.08 vs -0.44). Fair value of $432 based on $24 forward EPS at 18x supports trimming at $444 into confirmed momentum divergence, while preserving exposure to the genuine Q2 fundamental inflection and catalyst optionality.
| Position | Action |
|---|---|
| Current price $444 with triple-confirmation trigger active (extension + MACD divergence + negative EPS revisions) | Trim 20-25% of existing long exposure |
| Residual position post-trim | Hold 3-5% of portfolio |
| Re-entry trigger at $420-$432 (Bollinger middle/10 EMA confluence) with MACD bullish crossover + RSI <60 | Add 25-33% of intended re-engagement size |
| Re-entry trigger at $394-$415 (50 SMA zone) with confirmed basing pattern + bullish reversal candle | Add 25-33% of intended re-engagement size (contingent, not pre-committed) |
AMGN's pipeline catalysts (Tezspire EoE, Repatha mortality data) remain largely unpried in at a forward P/E of 18.2x with 51% EPS growth expected, representing a structural mispricing in a trending uptrend.
| Indicator | Value | Signal |
|---|---|---|
| close | 444.12 | neutral |
| rsi | 69.26 | neutral |
| macd | 14.21 | bearish |
| macd_signal | 15.29 | neutral |
| macd_histogram | -1.08 | bearish |
| sma_10_ema | 436.46 | bullish |
| sma_50 | 393.59 | bullish |
| sma_200 | 353.69 | bullish |
| bollinger_upper | 454.48 | neutral |
| bollinger_middle | 428.90 | neutral |
| bollinger_lower | 403.33 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price $394-$415 (50 SMA zone) + confirmed basing pattern + bullish reversal candle
Then: Re-engage 25-33% of intended size (contingent)
Forward P/E compression signals massive earnings expansion ahead, not a 'priced-in' stock
· concedes: Bear raises valid concerns about RSI 69 overbought reading and post-earnings 8.6% rally potentially pricing in near-term catalysts; Bear correctly notes negative tangible book value from Horizon acquisition; Bear's TTM P/E of 27.55x is technically accurate though backward-looking
AMGN's quality franchise is not worth buying at current stretched valuations; the technical setup shows mature-trend extensions with rolling momentum, the 51% EPS growth consensus is fantasy math requiring unprecedented quarterly performance, pipeline catalysts are largely already priced in, and the asymmetric payoff favors defensive positioning or shorting over aggressive buying at $444.
EV: -$221 to $285 (bear to base case over 12-18 months) · concedes: AMGN is a quality franchise with real cash flow; Pipeline catalysts are real; The structural uptrend may remain intact temporarily; Near-term momentum can remain elevated for months in strong trends; 0.41 beta and 21% net margin provide defensive characteristics; IRA risk is known and priced by some investors
→ vs conservative: Trim 25-33% of existing exposure at current levels means selling into strength on a normal consolidation while two fresh clinical wins sit unpriced in the stock; the recommended pullback zone of 394-415 was just tested and missed
→ vs neutral: HOLD is the centrist compromise that leaves returns on the table; AMGN in September 2026 with Repatha mortality data and Tezspire Phase 3 CROSSING win is not a neutral setup
| atr | 9.57 | neutral |
Support: 436.46 · 428.9 · 403.33 · 393.59 | Resistance: 454.48 · 445.82
AMGN shows a powerful long-term uptrend with price 25.5% above the 200 SMA and 12.8% above the 50 SMA, but short-term momentum is decelerating with MACD below its signal line (histogram −1.08) and RSI approaching overbought at 69.26. Key resistance sits at the Bollinger upper band (454.48), while support aligns with the 10 EMA (436.46) and Bollinger middle (428.90). The report assigns a HOLD rating with a bullish bias, advising existing holders to trail stops to the 10 EMA and recommending new entrants wait for a pullback to the $436–$429 zone for improved risk-reward.
Market Cap
$240.1B
P/E (TTM)
27.55x
Forward P/E
18.20x
PEG Ratio
2.11
P/B
20.54x
Dividend Yield
2.28%
Beta
0.41
52-Week High
$447.03
52-Week Low
$269.77
50-Day MA
$393.52
200-Day MA
$357.43
Total Revenue (TTM)
$38,095M
Gross Profit (TTM)
$27,387M
Gross Margin %
71.9%
Operating Income (TTM)
$14,082M
Net Income (TTM)
$8,743M
Diluted EPS (TTM)
$16.12
EBITDA (TTM)
$17,268M
Forward EPS
$24.40
Cash & Equivalents (Q2'26)
$13.99B
Total Debt (Q2'26)
$57.30B
Long-Term Debt (Q2'26)
$51.86B
Net Debt (Q2'26)
$43.32B
Stockholders' Equity (Q2'26)
$11.69B
Total Assets (Q2'26)
$95.64B
Working Capital (Q2'26)
$9.46B
Debt-to-Equity (D/E)
490.3
Total Debt / EBITDA
~3.3x
Net Debt / EBITDA
~2.5x
Current Ratio
1.37
Tangible Book Value
–$27.5B
Operating Cash Flow (TTM)
$8.65B
CapEx (Quarterly Q2'26)
$0.51B
Free Cash Flow (TTM)
$8.65B
FCF Yield
~3.6%
Quarterly Dividends
$1.36B
Operating Margin (TTM)
35.5%
Net Profit Margin (TTM)
22.95%
ROE
91.5%
ROA
8.7%
Revenue Growth YoY (Q2'26)
+9.5%
EPS Growth (Forward Expected)
~51%
Goodwill
$18.7B
Intangibles
$20.5B
Horizon Acquisition Cost
$27.7B
Dividend Payout Ratio
~63%
Annual Dividends Paid (FY2025)
$5.12B
Strengths
Concerns
HOLD – Amgen presents a mixed fundamental picture with top-line acceleration (+9.5% YoY to $10.05B in Q2'26), margin recovery (71.9% gross margin up from 61.5% trough), ongoing deleveraging ($43.3B net debt from $48.2B), and strong FCF generation ($8.65B TTM) supporting the bullish narrative; however, the stock trades at near all-time highs with stretched forward valuation expectations (PEG 2.11, 51% EPS growth consensus), elevated leverage ($57.3B total debt), and a tight dividend payout ratio (~63% of FCF). The prudent posture is to hold existing positions while waiting for either a pullback toward the 50-day MA (~$394) for tactical adds, or Q3'26 earnings confirmation (typically late October) before establishing new full-size longs.
Macro: Fed is pricing hawkish hold through year-end with only 1% implied probability of September cut (-0.9pp weekly), 4% for October (-1.4pp), and 12% for December (+0.5pp). US recession odds at 7% by end-2026 (-1.5pp). Higher-for-longer rate backdrop is mild headwind for high-multiple growth biotech but largely neutral for Amgen as profitable, cash-generative large-cap pharma with ~21% net margin and $8.1B FCF. Geopolitical premium contained; no direct read-through to Amgen's commercial book.